Why GSK picked Sabin to advance its Ebola vaccines

Making good on a recent proposal by GSK’s Rino Rappuoli on how best to develop vaccines, GSK has handed off clinical Ebola and Marburg vaccine candidates to Sabin Vaccine Institute as the pharma looks to partner with

Read the full 373 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE